retatrutide vs orforglipron trial results news today Lilly's triple agonist achieves 16.8% weight loss in phase 3 Lilly oral GLP-1 phase – See how Orforglipron compares to

How will impacted employers and members know about this change

The dual incretin mechanism GLP-1 receptor agonists engage the GLP-1 receptor across the pancreas, hypothalamus, and gastrointestinal tract, slowing gastric emptying, blunting post-meal glucose spikes, reducing appetite, and increasing satiety signaling

4-6% placebo Diarrhea: 12-17% Vomiting: 5-10% Constipation: 6-11% Decreased appetite: 5-11% GI events are predominantly mild-moderate and occur mainly during dose escalation (first 4-8 weeks), with significant attenuation over time Serious adverse events of interest : Pancreatitis : Adjudicated pancreatitis events occurred at rates of approximately 0.1-0.2% across the SURPASS program, comparable to rates seen with GLP-1 agonists

Many communities have pharmaceutical take-back programs or events where medications can be safely disposed of, and some pharmacies offer disposal services for medications they have dispensed